Factor VIII/von Willebrand factor - CSL Behring

Drug Profile

Factor VIII/von Willebrand factor - CSL Behring

Alternative Names: Aleviate; Biostate; Voncento

Latest Information Update: 25 May 2015

Price : $50

At a glance

  • Originator CSL Behring
  • Class Antihaemorrhagics; Blood coagulation factors; Coagulants; Recombinant proteins
  • Mechanism of Action Blood coagulation factor replacements; Factor X stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Haemophilia A; Von Willebrand disease

Most Recent Events

  • 29 Apr 2016 Biomarkers information updated
  • 31 Aug 2013 CSL Behring completes a phase III trial in Von Willebrand's disease (in children) in Belarus, Georgia, Germany, Guatemala, Lebanon & Ukraine (NCT01213446)
  • 30 May 2013 The CHMP adopts a positive opinion recommending marketing authorisation for factor VIII/von Willebrand factor for the prevention and treatment of bleeding in Haemophilia A and Von Willebrand disease in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top